Open AccessRole of interleukin‑32 in cancer biology (Review)
Author(s) -
Huanhuan Yan,
Donghua He,
Xi Huang,
Enfan Zhang,
Qingxiao Chen,
RuiHua Xu,
Xinling Liu,
Fuming Zi,
Zhen Cai
Publication year - 2018
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2018.8649
Subject(s) - cancer , biology , oncogene , proinflammatory cytokine , interleukin , cancer research , tumor microenvironment , molecular medicine , cytokine , cancer cell , cell cycle , immunology , cancer immunology , inflammation , immunotherapy , genetics
Interleukin-32 (IL-32), a novel proinflammatory cytokine, is highly expressed in various cancer tissues and in established cancer cell lines. IL-32 has been revealed to serve a crucial role in human cancer development, including tumour initiation, proliferation and maintenance. The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment. Understanding the underlying mechanisms of IL-32 expression and its function are critical for the discovery of novel therapeutic strategies that target IL-32. This is a review of the current literature on the regulation and function of IL-32 in cancer progression, focusing on the molecular pathways linking IL-32 and tumour development.